Objectives: To examine changes the in use of prescription opioids for the management of chronic noncancer pain in human immunodeficiency virus (HIV)-infected patients and to identify patient characteristics associated with long-term use.
T he introduction of combination antiretroviral therapy (ART) in 1996 has resulted in substantially decreased mortality and acquired immunodeficiency syndrome (AIDS)-related morbidity for human immunodeficiency virus (HIV)-infected individuals. As a result, the HIVinfected population in developed countries is rapidly aging, with those >50 years of age one of the fastest growing demographics. 1, 2 HIV patient care, therefore, has shifted to a chronic disease model focusing on lifelong use of therapy, management of side effects, and increasing focus on agerelated comorbidities.
For many patients, lifelong infection and treatment is accompanied by high rates of pain and other clinical symptoms, with some studies indicating that up to two-thirds of patients on ART experience clinical symptoms, most commonly gastrointestinal symptoms, body fat redistribution, myalgias, and paresthesias. 3, 4 Pain in HIV-infected patients is generally chronic, 5 and results in significantly reduced quality of life. 6 Thus, effective chronic pain management is an important consideration for HIV-infected patients, and an option for chronic pain management that is increasingly common in the general population is long-term use of opioid analgesics. 7 However, long-term treatment of pain with opioid analgesics in HIV-infected patients is complex given concerns of possible drug misuse as many HIV-infected individuals have a drug abuse history. 8 Furthermore, there are known drug-drug interactions for all antiretroviral drug classes with methadone and buprenorphine, [9] [10] [11] [12] and also for other opioid analgesics, including meperidine 10 and fentanyl 13 coadministered with ritonavir-boosted antiretrovirals.
The use of opioids for the treatment of chronic pain has increased markedly in the US, 14 but there has been no evaluation of changes over time in opioid prescribing among HIV-infected individuals, nor a comparison of opioid prescribing in HIV-infected individuals with the general population. This study compares trends in opioid prescribing between HIV-infected and HIV-uninfected individuals enrolled in two large integrated health plans between 1997 and 2005. We also evaluated whether demographic and HIV-associated clinical factors were associated with long-term prescription opioid use in HIVinfected individuals.
MATERIALS AND METHODS

Study Setting, Design, and Population
The analysis was performed within the CONsortium to Study Opioid Risks and Trends (CONSORT), 15 which has the overall study goal to examine determinants and risks of long-term opioid therapy for the treatment of chronic noncancer pain. Eligible participants included individuals at least 18 years of age without a history of cancer, identified from 2 large integrated health plans: Kaiser Permanente Northern California (KPNC) and Group Health Cooperative (GHC) in Washington state. The CONSORT study period was from 1997 to 2005, corresponding to availability of comprehensive electronic clinical data at both health plans. Both health plans serve employed persons, older populations enrolled in Medicare, and lower-income persons insured by Medicaid and State health insurance programs for low-income populations. The health plans offer primary care as well as specialty services. Together, these health plans provide care for >4 million members, with demographic profiles similar to the catchment areas. 16, 17 HIV-infected and HIV-uninfected CONSORT individuals within KPNC comprised the primary source population for analysis because of the larger sample size and additional available risk factor data (eg, race/ethnicity and HIV transmission risk factor). GHC data was used principally for confirmation of opioid prescription calendar trends. The institutional review boards at each institution approved the study, providing waivers of informed consent.
Data Sources
The CONSORT study uses automated health plan data, including information on pharmacy use, laboratory tests (CD4 and HIV viral load), patient demographics (age and sex), enrollment, and clinical diagnoses (substance use disorders, depression diagnoses, and other comorbidities). 15 Information on medical encounters and pharmacy utilization were captured for all services provided directly by the health plans, and through claims data for any covered services provided outside of the health plan. The pharmacy databases were used to identify all dispensed opioid and antiretroviral prescriptions. The pharmacy files contain 1 record/drug dispensed, including generic drug name, strength, directions for use, date dispensed, quantity dispensed, days supply, prescriber identification number, and National Drug Code. Surveys at both plans indicated that pharmacy databases capture >90% of membership prescriptions. 16, 17 Methadone for the treatment of opiate disorders would need to be obtained from outside community agencies as the health plans do not cover such treatments. During the study period, buprenorphine was also not provided for addiction treatment. Thus, these prescriptions identified in pharmacy databases for the study period would be for pain rather than for opioid addiction. Opioid prescriptions in both health plans are generally limited to a 30-day supply only.
Substance use disorders were defined as medical encounters with ICD-9 codes indicating drug and alcohol abuse or dependence. We previously found that a third of such diagnoses among KPNC members were received exclusively from Chemical Dependency or Psychiatry departments. 18 For this analysis, we computed a modified Charlson comorbidity score, 19 based on inpatient and outpatient diagnoses excluding those related to HIV or AIDS. The KPNC HIV Registry, as described previously, 2 includes all known cases of HIV infection since the early 1980s. The GHC HIV registry includes cases identified since 1993. HIV infection status for all cases was confirmed by medical chart review or comparisons of case lists with HIV clinics. Race/ ethnicity and HIV-transmission risk factor data was additionally collected by chart review for KPNC only. Patients without verified HIV status were excluded from the respective HIV registries.
Prevalent Long-term Prescription Opioid Use
The primary outcome for this analysis was prevalent long-term prescription opioid use, defined in CONSORT using an opioid episode-based approach. 15 The beginning of an episode was defined by the date of dispensing of an opioid (oral or transdermal) without a previous dispensing in the prior 6 months. An episode ends with the last opioid dispensing with no additional dispensing in the following 6 months. The end date was defined as the date of last prescription and days supply for that prescription. An episode was considered long-term, as described in detail previously, 15 if it was both longer than 90 days and associated with either a 120+ total days supply (ie, sum of days supply for each opioid dispensed during an episode) or 10 or more opioid prescriptions dispensed within a given year. For each study year, 1997 to 2005, we identified prevalent episodes defined as those ongoing at any time during the calendar year of interest. Prevalent episodes were identified among individuals enrolled for the entire year and 182 days after the end of the year to ensure enough time to observe long-term use after an episode began.
Medication Use Profiles
Characteristics of HIV-infected and HIV-uninfected long-term opioid users were compared using a core set of variables (ie, medication profiles) developed in CONSORT as described previously. 15, 18 The population for the medication profile analysis consisted of prevalent users in an episode of long-term opioid use on January 1, 2005, who also met the criteria for long-term use in 2005. Prevalent episodes may have started before January 1, 2005 and extended beyond December 31, 2005. However, the medication profile measures correspond to only long-term use during 2005.
Several medication profile variables were based on the total days supply during a calendar year and types of medications prescribed, including average total days supply, % mainly Schedule II, % mainly long-acting Schedule II, and % with concurrent 180+ Days Supply Sedative-Hypnotics. The opioid with the longest total days supply was used to classify episodes as mainly Schedule II or mainly longacting Schedule II. Short-acting, Schedule II medications included morphine sulfate, codeine sulfate, hydromorphone, meperidine, fentanyl transmucosal, oxymorphone, and oxycodone. Long-acting, Schedule II medications included morphine sulfate sustained release (SR), fentanyl transdermal, levorphanol, oxycodone controlled release, methadone, hydromorphone SR, and oxymorphone SR. Other medication profile variables involved first calculating morphine equivalents for each opioid dispensed as follows: quantity x the strength (ie, milligrams per unit dispensed) x drug-specific conversion factors. 15 Total morphine equivalents were calculated by adding the morphine equivalents for each opioid dispensed during the episode. Average prescribed dose is the total morphine equivalents divided by total days supply for the episode. Average daily dose is the total morphine equivalents divided by episode duration in days. Average daily dose is an estimate of mean daily consumption, whereas average prescribed dose approximates the maximum intended daily dose. Finally, high dose episodes were defined as those with an average daily dose of Z20 mg, based on thresholds developed previously. 20 
Statistical Methods
For each study year, 1997 to 2005, we first examined the annual prevalence of long-term opioid use episodes per 100 individuals, separately by health plan and by HIVinfection status. We then estimated the annualized percent change in prevalent opioid use across the 9-year study period with 95% confidence intervals obtained using a linear regression method described by Fay et al. 21 The linearized annualized percent change estimates the constant annual (multiplicative) rate of change in prevalence over a fixed time period [eg, 100Â(prevalence time 2 Àprevalence time 1 )/ prevalence time 1 )]. The annualized percent change was standardized to the 2005 age-sex distribution of the KPNC general population. Next, analyses were performed separately for years 1997 and 2005, to study whether determinants of long-term opioid therapy have changed over time. Initially, we described characteristics of KPNC HIV-infected members with and without prevalent long-term opioid therapy in 1997 and 2005. Next, we evaluated the association of patient characteristics and prevalent long-term prescription opioid use for years 1997 and 2005. Characteristics evaluated were age, sex, race/ethnicity, years known HIVinfected (as of January 1), HIV transmission by injection drug use, any earlier use of antiretrovirals (as of January 1), CD4 + T-cell count and HIV viral load (most recent test in prior year), any earlier diagnosis of AIDS (as of January 1), recent clinical depression diagnoses (within 2 years before January 1), Charlson comorbidity scores (within 2 years before January 1), and recent substance use disorders (within 2 years before January 1). Depression, Charlson comorbidity scores, and substance use disorder diagnoses were unavailable for analysis of 1997 data. Adjusted prevalence ratios (PR) were obtained from modified Poisson regression models with robust standard errors 22 using Proc Genmod in SAS (Version 9.1, Cary, NC). Finally, we compared medication use profiles between HIV-infected and HIVuninfected KPNC members with long-term prevalent opioid use. We presented unadjusted medication profile measures, but P values comparing results to the KPNC general population by HIV infection status were age-and sex-adjusted.
RESULTS
Descriptive characteristics for KPNC HIV-infected individuals with and without long-term prevalent use in 1997 and 2005 are presented in Table 1 . In total, 6939 HIVinfected KPNC members were eligible for 1 or more calendar years between 1997 and 2005, with a median of 4 eligible years contributed per person. Univariate comparisons in 2005 indicated that prescription opioid users compared with nonusers, were older, more often female, white, African-American, had more years known HIVinfected, more likely to report prior injection drug use, to have a prior depression diagnosis, have higher Charlson comorbidity scores, and less often Hispanic, other race/ ethnicities, and men who have sex with men. Prevalent users compared with nonusers also had lower CD4 + T-cell counts, higher HIV viral load, and higher percentages with prior AIDS diagnoses and ART experience. Similar results comparing users and nonusers were observed in 1997 ( Table 1 ). All differences in these baseline measures between HIV-infected long-term opioid users and nonusers were statistically significant at P<0.05.
The age and sex distribution comparing HIV-infected individuals in KPNC and GHC were similar ( Table 2) . HIV-uninfected members in both health plans were older and more likely female individual compared with HIVinfected members of the same health plan, particularly among prevalent users. Annual prevalence for long-term opioid prescription use is presented in Figure 1 for HIVinfected and HIV-uninfected individuals. In KPNC, the unadjusted prevalence of long-term opioid use increased only slightly among HIV-infected individuals from 7.0% in 1997 to 8.0% in 2005, corresponding to an age-adjusted and sex-adjusted annualized percent change of 4.0% (95% CI, 0.8-7.3). Among KPNC HIV-uninfected individuals, the unadjusted prevalence increased from 2.1% in 1997 to 3.9% in 2005, corresponding to an age-adjusted and sexadjusted annualized percent change of 8.4% (95% CI, 8.1-8.7). The difference in trends comparing HIV-infected with HIV-uninfected individuals was statistically significant (P<0.05). The pattern was similar at GHC where prevalence increased only slightly between 1997 and 2005 from 8.4% to 8.5% for HIV-infected individuals, but increased 2.3% to 4.7% in HIV-uninfected individuals. The difference in overall trends at GHC by HIV infection status were also statistically significant (P<0.05).
As shown in Table 3 for 1997, statistically significant associations (P<0.05) with prevalent long-term opioid use were observed for female sex with a PR of 2.0 (95% CI=1.3, 3.0); history of injection drug use with a PR of 2.1 (95% CI=1.5, 3.2); recent higher HIV viral load with a PR of 1.2 per log unit increase (95% CI=1.0, 1.4); and prior AIDS with a PR of 2.0 (95% CI=1.2, 3.1). In 2005, significant associations were observed for age 40 to 49 years (compared with 18 to 39 y) with a PR of 1.6 (95% CI=1.1, 2.4); female sex with a PR of 1.8 (95% CI=1.3, 2.5); 10 or more years known HIV-infected (compared with <5 y) with a PR of 1.5 (95% CI=1.1, 2.2); history of injection drug use with a PR of 1.9 (95% CI=1.4, 2.7); Charlson comorbidity scores Z2 (compared with 0) with a PR of 1.9 (95% CI=1.4, 2.8) and scores of 1 (compared with 0) with a PR of 1.6 (95% CI=1.2, 2.1); depression with a PR of 1.3 (95% CI=1.0, 1.7); and, substance use disorders with a PR of 1.9 (95% CI=1.4, 2.6).
Finally, we compared medication use profiles for 204 HIV-infected and 37,377 HIV-uninfected individuals with a prevalent long-term opioid use episode in 2005 (Table 4 ). HIV-infected individuals had higher average prescribed and daily doses, and higher percentages of high dose, mainly Schedule II drugs, mainly long-acting Schedule II drugs, and 180+ days supply sedative hypnotics. However, with adjustment for age and sex, none of these differences remained statistically significant.
DISCUSSION
In this study, we determined that long-term prevalent opioid prescription use was more common among HIVinfected individuals compared with the general population. However, prevalence was increasing dramatically in the general population but was stable in the HIV-infected population. The strongest predictors of prevalent long-term opioid use in the HIV-infected population were female sex, HIV transmission by injection drug use, prior comorbidities and substance use disorders. Certain characteristics including older age and longer years known HIV-infected were only associated with prevalent long-term opioid use in 2005, while clinical characteristics, including higher HIV viral load and a diagnosis of AIDS were only associated with prevalent opioid use in 1997. Depression diagnoses were also significantly associated with prevalent opioid use. To our knowledge, this is the first analysis of trends in the use of long-term prescription opioid use for the manage-ment of chronic pain in HIV-infected patients. The trends observed among study participants in Northern California were supported by similar trends among the study participants in Washington State.
The higher prevalence of prescription opioids in HIVinfected individuals likely reflects the overall higher prevalence of chronic pain resulting from HIV-related complications (eg, opportunistic infections) and/or side effects of treatment. 23 However, it is notable that we observed a less rapid increase in opioid prescribing for HIV-infected patients compared with a doubling of the prevalence for the general population. It has been suggested that the increases in the general population may be due to either more pain-related diagnoses over time, or more likely, better patient and provider attention to pain and pain management. 7 The more stable prevalence over time in HIV patients may reflect opposing pressures on pain management and etiology over time. First, this analysis started near the beginning of the ART era when HIV/AIDS was transformed from a terminal illness to a chronic disease. 24 Therefore, earlier in the ART era, opioid management was more likely part of palliative, end-of-life care and consequently more liberal. Over time, the clinical management of HIV patients overall has improved, including substantial reductions in HIV-related complications and improved tolerability of newer generation antiretrovirals. 12 To offset this tendency for a decreased prevalence of prescription opioids over time, there are likely other factors resulting in a tendency for an increased prevalence. First, a consequence of the improved survival in the ART era for HIV patients is the higher burden of non-AIDS-related comorbidities, 25, 26 resulting in the potential greater need for pain-related management. In support of this, we confirmed here that a higher comorbidity burden was a strong predictor of long-term prevalent opioid use. Second, HIV patients are also likely benefiting from improvements in pain management. Although we could not directly assess this possibility, it is noteworthy that older age and more years of HIV experience were associated with higher prevalent opioid use in 2005, but not in 1997. These results likely reflect the growing numbers of patients in these subgroups, accompanied by an increasing inclination for the treatment of pain in HIV patients with the longest exposure to HIV and/or prolonged exposure to antiretrovirals. Together, these opposing pressures on pain etiology and management may explain the stable trends in use of pain medication for HIV patients relative to the large increases observed for the population at large.
Long-term use of prescription opioids was strongly associated with HIV transmission by injection drug use, and substance use disorders diagnosed within the prior 2 years. These 2 factors were related in our data, but included little overlap. To illustrate, in 2005, of those with a substance use disorder in the prior 2 years, 16% had an HIV transmission risk factor of injection drug use compared with only 5% among those without prior substance use disorders. Thus, most HIV-infected individuals identified here with a prior substance use disorder did not have a recorded HIV exposure transmission of injection drug use. This is relevant as such diagnoses if made in the Chemical Dependency or Psychiatry departments, may not have been known to prescribing physicians outside these departments, including HIV clinicians. Diagnoses are not disclosed to such prescribing physicians because of Federal 42CFR Part 2 privacy regulations, which prohibit any disclosure of chemical dependency visits or diagnoses (or in the Psychiatry department when Chemical Dependency is affiliated with Psychiatry) to other departments in the same health plan. 27, 28 Thus, careful screening by the prescribing physician for the potential abuse of prescribed opioids or existence of a substance abuse problem is needed.
The association of drug abuse with prescription opioid use is consistent with earlier studies among HIV-infected individuals, 8, [29] [30] [31] and recent studies comparing prescription opioid use between those with and without substance use disorders in the general population. 18, 32 Those with diagnosed substance use disorders may have reduced pain tolerance, 23, 33 or perhaps increased prevalence of other comorbid illnesses, 34 resulting in more frequent use of prescription opioids at higher dosage levels. The higher prevalence of prescription opioid use in HIV patients with substance use disorders may also reflect increased risk of misuse of prescription opioids in this population. Tsao et al, 31 for example, evaluated 2267 HIV-infected individuals from 1996 to 1997 in the HIV Cost and Services Utilization study and found an increased risk of pain and aberrant opioid use among those with a drug abuse history (n=870) compared with those without a drug abuse history (n=1397). Those with a history of drug abuse also persistently reported aberrant opioid use during follow-up. Another study of 190 HIV-infected individuals seen in a single US medical clinic indicated that HIV-infected individuals with a history of injection drug use were more likely to have been prescribed narcotics inappropriately compared with other men who have sex with men or heterosexuals. 8 Clinical factors associated with prevalent long-term opioid use in this study were high HIV viral load, prior AIDS, prior depression, and other comorbidity diagnoses. HIV viral load and AIDS were associated with opioid use in 1997 but not in 2005, which again likely reflects the improving prognosis for HIV/AIDS patients over time and availability of better tolerated therapy. Other demographic factors associated with prevalent opioid use in our study were female sex, older age, and more years known HIVinfected. Prior studies have not evaluated such factors with respect to opioid prescribing, although some have reported that these same clinical factors were associated with reported clinical symptoms among HIV-infected persons. 4 In the absence of controlled trials evaluating the benefits and risks of long-term opioid use for chronic pain, it is difficult to know to what extent observed rates of longterm opioid use reflect excessive use of prescribed opioids in certain subgroups. Conversely, others have concluded that pain in HIV-infected patients may be undertreated. 29, 30, 35 Although our study did not address the appropriateness of opioid prescription use directly, it is noteworthy that we found no differences by HIV-infection status, after accounting for age and sex, in opioid dosing, or use of Schedule II drugs, suggesting that prescribing is similar in these populations. However, in a study of US Veterans seen between 1998 and 2001, Hermos et al 36 reported that oxycodone/acetaminophen prescription use in HIV + patients was more likely to be long term rather than short term or intermediate term, and more often associated with higher doses, suggesting a potential high-risk prescribing pattern. Thus, further analysis of the appropriate management of chronic pain in HIV-infected individuals is warranted.
There were study limitations. First, depression, substance use disorder diagnoses, and other medical comorbidity data were ascertained from automated diagnostic data, and may have been underreported, although not likely to be different between those with and without prescription opioid use. Furthermore, these variables were not available for analysis of factors associated with prescription opioid use in 1997. However, exclusion of these variables from the final multivariable model in 2005 had no effect on the magnitude of PRs for other variables (data not shown). Another limitation was the lack of information regarding indications for opioid prescribing, including types of pain experienced. Such information would be valuable for a refined understanding of the etiology and treatment of chronic pain in HIV patients.
An additional limitation is the lack of generalizability to those without health insurance or to other healthcare systems that are not guided by an integrated health care delivery model. However, the comparable trends observed within 2 separate health plan systems suggest highly generalizable results for other similar healthcare systems with comprehensive medical coverage.
In summary, we determined that HIV-infected individuals have a higher prevalence of long-term prescription opioid use compared with the general population, although prevalence in the HIV-infected population was stable, whereas general population rates were increasing rapidly. HIV disease severity and HIV treatment experience were not predictive of opioid use in the most recent study year, suggesting improvements over time in the tolerability of antiretrovirals. We also determined that certain subgroups had increased long-term opioid use, particularly those with a history substance use disorders. These results are relevant to strategies for management of chronic pain in HIVinfected individuals. Specifically, careful screening for substance use problems is warranted when considering long-term medically prescribed opioids in this population.
